TeleflexTFX +1.26%76 5-Year Yield-on-Cost % is 1.00 as of Jul. 13, 2026, which is 82% above its 10-year median of 0.55. GuruFocus rates TFX with a GF Score™ of 76/100 and a GF Value™ of $182.20 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 327 Medical Devices & Instruments companies, Teleflex ranks worse than 74.31% on this metric.
Teleflex's yield on cost for the quarter that ended in Mar. 2026 was 1.00.
The historical rank and industry rank for Teleflex's 5-Year Yield-on-Cost % or its related term are showing as below:
TFX'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.31 Med: 0.55 Max: 1.32
Current: 1
During the past 13 years, Teleflex's highest Yield on Cost was 1.32. The lowest was 0.31. And the median was 0.55.
TFX's 5-Year Yield-on-Cost % is ranked worse than 74.31% of 327
companies
in the Medical Devices & Instruments industry
Industry Median: 2.37
vs TFX: 1.00
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Teleflex 5-Year Yield-on-Cost % Related Terms
TFX vs STVN, AVTR, NVST: 5-Year Yield-on-Cost % Comparison
For the Medical Instruments & Supplies subindustry, Teleflex's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Teleflex 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Teleflex's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Teleflex's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Teleflex is calculated as
Teleflex (TFX) has a 5-Year Yield-on-Cost % of 1.00 as of Jul. 13, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Teleflex and its competitors. This is 82% above median its historical median of 0.55. Over the past decade, Teleflex's 5-Year Yield-on-Cost % has ranged from 0.31 to 1.32. According to the industry distribution chart, Teleflex ranks #243 out of 327 companies in the Medical Devices & Instruments industry, placing it in the top 74.3%.
Is Teleflex's 5-Year Yield-on-Cost % too high?
Teleflex's current 5-Year Yield-on-Cost % of 1.00 is 82% above median its 10-year median of 0.55. Over the past 10 years, this metric has ranged from a low of 0.31 to a high of 1.32. The Medical Devices & Instruments industry median 5-Year Yield-on-Cost % is 2.37. Teleflex's value of 1.00 is 57.8% below this industry median. Based on the distribution chart, Teleflex ranks #243 out of 327 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Teleflex has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Teleflex's 5-Year Yield-on-Cost % compare to STVN and AVTR?
According to the Medical Devices & Instruments industry distribution chart, Teleflex ranks #243 out of 327 companies for 5-Year Yield-on-Cost %. This places Teleflex in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.37. Teleflex's value of 1.00 is 57.8% below this benchmark. Historically, Teleflex's own 5-Year Yield-on-Cost % has ranged from 0.31 to 1.32 over the past decade. While the company's 10-year median is 0.55 vs. the industry median of 2.37, Teleflex has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.37, based on 327 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Teleflex's current 5-Year Yield-on-Cost % of 1.00 is 57.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Teleflex and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Teleflex's current 5-Year Yield-on-Cost % is 1.00, which is 82% above median its own 10-year median of 0.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Teleflex stock overvalued right now?
Based on GuruFocus' analysis, Teleflex (TFX) is currently considered Modestly Undervalued. The stock's GF Value™ is $182.20, compared to a current price of $135.73 — trading 25.5% below its estimated fair value. The current 5-Year Yield-on-Cost % is 1.00, which is 82% above median its 10-year median of 0.55 and 57.8% below the Medical Devices & Instruments industry median of 2.37. Teleflex's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Teleflex (TFX), the current 5-Year Yield-on-Cost % is 1.00 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Teleflex (TFX) Overvalued in 2026?
Based on GuruFocus' analysis, Teleflex stock appears to be undervalued.
The current stock price of $135.73 is trading 25.5% below its estimated GF Value™ of $182.20.
GuruFocus considers Teleflex to be Modestly Undervalued.
Key valuation signals for TFX:
5-Year Yield-on-Cost %: 1.00 (82% above median its 10-year median of 0.55)
GF Value™: $182.20 vs. price of $135.73 (25.5% below fair value)
Industry Position: 57.8% below the Medical Devices & Instruments median (#243 of 327)
No single metric tells the full story. See the TFX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Teleflex Inc is a provider of medical technology products focused on enhancing clinical benefits, improving patient and provider safety and reducing total procedural costs. It designs, develops, manufactures and supply medical devices used by hospitals and healthcare providers supporting high-acuity emergent procedures. The company has three reportable segments: Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). It derives maximum revenue from Americas. Its products includes: Anaesthesia, Emergency Medicine, Interventional Cardiology/Radiology, Interventional Urology - UroLift System, Surgery, Urology, and Vascular Access.
76GF Score
Get the complete analysis for TFX
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TFX has been successfully added to your 